What You Should Know
- Ambient clinical AI pioneer Nabla has appointed Brian Manning as Chief Executive Officer to scale its enterprise go-to-market execution and global expansion.
- Manning previously served as President and CRO at Bamboo Health (scaling ARR to $140M+), led GTM strategy at PatientPing through its acquisition, and helped launch the enterprise sales engine at Zocdoc.
- Co-founder and former CEO Alex LeBrun moves to Executive Chairman and Chief AI Officer, focusing strictly on Nabla’s AI strategy, model development, and frontier research.
Pairing Commercial Scale with Frontier AI Research
Brian Manning brings over two decades of experience expanding healthtech platforms. Most recently as President and CRO of Bamboo Health, he scaled the organization past $140 million in annual recurring revenue (ARR) and 300 employees. His background also includes building PatientPing’s GTM engine from early-stage through its successful acquisition, alongside launching enterprise sales at Zocdoc.
“Brian is the right leader to help Nabla build on the exceptional foundation our team has created,” said Alex LeBrun, Executive Chairman and Chief AI Officer at Nabla. “Brian has a rare ability to build organizations that pair commercial excellence with long-term vision. As healthcare enters a new era of AI, that combination is exactly what’s needed to extend Nabla’s leadership as we build the clinical AI layer for modern healthcare.”
Manning joins a founding leadership team—including COO Delphine Groll, CTO Martin Raison, and CPO Laurent Landowski—that has built immense commercial momentum:
- Clinicians Supported Nationwide: 100,000+ Clinicians
- Healthcare Systems Deployed: 190+ Health Systems
- Annual Patient Encounters Handled: 40 Million Encounters
- Multilingual Support Capabilities: 35+ Languages Supported
Former CEO Alex LeBrun will now focus exclusively on advancing Nabla’s technological moat as Chief AI Officer. LeBrun also serves as CEO of AMI Labs, a frontier AI research company founded alongside Turing Award winner and Meta’s former Chief AI Scientist, Yann LeCun. Having secured over $1.2 billion in research capital, AMI Labs maintains an exclusive partnership with Nabla—giving Nabla direct, early access to breakthrough “world models” designed to transform clinical intelligence.
“What attracted me to Nabla is the combination of its outstanding team, crucial mission, product excellence, and customer obsession,” noted Manning. “The opportunity now is to accelerate that momentum, expand our reach, and further establish Nabla as the clinical AI partner of choice for healthcare organizations across the world.”
